Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.

This rapid development is considered a positive trend, as these medicines are offering a new and innovative approach with the recent breakthrough in haematological malignancies changing the therapeutic approach to oncology [ 27 , 29 ].

also in 11,005 other papers